Structures by: Shankland K.
Total: 138
CF3LiO3S
CF3LiO3S
Journal of Solid State Chemistry (1992) 100, 191-196
a=10.2432(2)Å b=5.0591(1)Å c=9.5592(3)Å
α=90.° β=90.319(2)° γ=90.°
C27H26N2O6S
C27H26N2O6S
Organic letters (2013) 15, 6 1386-1389
a=6.945(3)Å b=17.2536(5)Å c=20.6291(10)Å
α=90.00° β=90.00° γ=90.00°
(+)-Ethyl (2R,4S-dinitro-3R-phenyl-1S-cyclohexyl) acetate
C16H20N2O6
Chemical Science (2012) 3, 2 584
a=7.95486(5)Å b=10.00542(6)Å c=20.80472(17)Å
α=90.0° β=90.0° γ=90.0°
Ethyl 2(R)-[3(R)-(4'-methoxy-phenyl)-2(R),4(S)-dinitro-1(R)cyclohexyl] propanoate
C18H24N2O7
Chemical Science (2012) 3, 2 584
a=5.5811(5)Å b=12.5943(15)Å c=26.723(4)Å
α=90.00° β=90.00° γ=90.00°
Ethyl 2-[(1S,2R,3R,4S)-2-methyl-2,4-dinitro-3- phenylcyclohexyl]acetate
C17H22N2O6
Chemical Science (2012) 3, 2 584
a=10.1928(5)Å b=6.6518(4)Å c=12.7044(6)Å
α=90.00° β=93.098(5)° γ=90.00°
Ethyl (2R)-2-[(1R,2R,3R,4S)-3-(4-methoxyphenyl)- 2,4-dinitrocyclohexyl]propanoate
C18H24N2O7
Chemical Science (2012) 3, 2 584
a=12.8847(13)Å b=5.6274(5)Å c=25.767(2)Å
α=90.00° β=92.776(9)° γ=90.00°
C5H10
C5H10
The journal of physical chemistry. B (2008) 112, 12 3746-3758
a=9.578(5)Å b=5.328(2)Å c=10.018(2)Å
α=90.00° β=113.12(3)° γ=90.00°
Zopiclone
C17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=15.2023(4)Å b=7.1510(1)Å c=17.6577(3)Å
α=90.0° β=111.213(1)° γ=90.0°
Zopiclone dihydrate
C17ClN6O3,2(O)
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=16.4834(1)Å b=7.1465(1)Å c=17.4026(1)Å
α=90.0° β=109.8065(4)° γ=90.0°
Zopiclone
C17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=5.5813(1)Å b=8.8467(1)Å c=35.6588(3)Å
α=90.0° β=90.0° γ=90.0°
Zopiclone
C17H17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=5.50540(10)Å b=8.7686(2)Å c=35.5277(7)Å
α=90.00° β=90.00° γ=90.00°
Zopiclone
C17H17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=5.50230(10)Å b=8.7676(2)Å c=35.5314(7)Å
α=90.00° β=90.00° γ=90.00°
Zopiclone dihydrate
C17H21ClN6O5
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=16.374(4)Å b=7.030(3)Å c=17.185(2)Å
α=90° β=108.62(1)° γ=90°
(3'aR,6'R,6'aR,7R)-2',2'-dimethyl-octahydro-3'aH-spiro[[1,2,3]triazolo[4,3-c][1,4]oxazine-7,4'-furo[3,4-d][1,3]dioxol]-6'-ylmethanol
C12H17N3O5
New Journal of Chemistry (2018) 42, 22 18363
a=6.596(5)Å b=8.066(5)Å c=24.761(5)Å
α=90° β=90° γ=90°
((6R,7S,8R)-7,8-dihydroxy-6-(hydroxymethyl)-5-oxa-2-azaspiro[3.4]octan-2-yl)(λ^3^-oxidaneylidyne)(p-tolyl)-λ^7^-sulfanone
C14H19NO6S
New Journal of Chemistry (2018) 42, 22 18363
a=13.1956(3)Å b=5.6323(2)Å c=20.3477(5)Å
α=90° β=91.524(2)° γ=90°
C7H7N3O4
C7H7N3O4
New Journal of Chemistry (2004) 28, 1 161
a=8.0136(3)Å b=8.0502(3)Å c=14.2752(5)Å
α=75.097(2)° β=74.059(2)° γ=78.453(2)°
C7H7N3O5
C7H7N3O5
New Journal of Chemistry (2004) 28, 1 161
a=15.0980(4)Å b=3.9219(1)Å c=16.4446(5)Å
α=90.00° β=116.586(2)° γ=90.00°
C7H7N3O4
C7H7N3O4
New Journal of Chemistry (2004) 28, 1 161
a=6.7072(5)Å b=16.0387(11)Å c=8.1083(5)Å
α=90.00° β=91.160(4)° γ=90.00°
Compound 2
C10H7N
New Journal of Chemistry (2003) 27, 1 140
a=5.9188(17)Å b=12.030(4)Å c=11.026(3)Å
α=90.00° β=104.17(2)° γ=90.00°
Compound 3
C10H5F
New Journal of Chemistry (2003) 27, 1 140
a=3.8780(11)Å b=5.9470(12)Å c=15.800(5)Å
α=90.00° β=93.46(3)° γ=90.00°
Compound 4
C10H4F2
New Journal of Chemistry (2003) 27, 1 140
a=3.8535(7)Å b=5.9060(10)Å c=16.221(5)Å
α=90.00° β=95.23(3)° γ=90.00°
Compound 5
C10H2F4
New Journal of Chemistry (2003) 27, 1 140
a=5.7642(9)Å b=11.4632(18)Å c=6.1120(10)Å
α=90.00° β=99.27(2)° γ=90.00°
C14H25ClN2
C14H25ClN2
New Journal of Chemistry (2002)
a=7.40022(11)Å b=8.56690(15)Å c=13.69231(32)Å
α=106.2107(14)° β=90.8532(11)° γ=98.7783(12)°
C52H48N2O4
C52H48N2O4
Chem.Commun. (2015) 51, 1143
a=20.5116(14)Å b=5.1146(4)Å c=21.4898(15)Å
α=90.00° β=116.490(2)° γ=90.00°
Dimethyl (2S,3R)-3-(3-bromophenyl)-2-cyano-2-(phenylsulfonyl)cyclopropane-1,1-dicarboxylate
C20H16BrNO6S
Chem.Commun. (2015) 51, 13558
a=8.30101(10)Å b=10.28989(17)Å c=23.4389(3)Å
α=90.0° β=90.0° γ=90.0°
N,N'-diphenyl-N,N'-bis(4,4'-methylphenyl)-[(1,1'-biphenyl)]-4,4'-diamine
C38H32N2
Journal of Materials Chemistry (2002) 12, 2 168
a=20.9674(3)Å b=14.5059(2)Å c=10.9862(1)Å
α=90.0° β=117.825(2)° γ=90.0°
5H-dibenz(b,f)azepine-5-carboxamide 10,11-dihydro-5H- dibenz(b,f)azepine-5-carboxamide (1/1)
0.5(C15H12N2O1),0.5(C15H14N2O1)
CrystEngComm (2006) 8, 10 746
a=9.088(2)Å b=10.425(4)Å c=25.005(7)Å
α=90.00° β=90.00° γ=90.00°
C38H32N2
C38H32N2
Journal of Materials Chemistry (2002) 12, 2 168
a=11.068(2)Å b=14.472(2)Å c=17.820(3)Å
α=90.00° β=90.00° γ=90.00°
Indomethacin Nicotinamide (1/1)
C19H16ClNO4,C6H6N2O
CrystEngComm (2013) 15, 20 4041
a=17.1980(8)Å b=5.0156(2)Å c=27.3815(15)Å
α=90° β=97.311(2)° γ=90°
10,11-Dihydro-5H-dibenzo(a,d)cycloheptene-5-carboxamide
C16H15NO
CrystEngComm (2008) 10, 1 26
a=5.6491(1)Å b=19.5639(4)Å c=22.0741(5)Å
α=84.2178(13)° β=88.4073(14)° γ=83.6001(13)°
7-Fluoroisatin Form I
C8H4FNO2
CrystEngComm (2008)
a=3.79560(10)Å b=11.9933(3)Å c=14.9907(4)Å
α=90.00° β=90.631(3)° γ=90.00°
7-Fluoroisatin Form II
C8H4FNO2
CrystEngComm (2008)
a=8.1207(13)Å b=8.2351(15)Å c=12.394(4)Å
α=70.87(2)° β=85.834(17)° γ=61.023(17)°
7-Fluoroisatin Form III
C8H4FNO2
CrystEngComm (2008)
a=7.1988(3)Å b=12.7677(5)Å c=14.9468(7)Å
α=90.00° β=91.702(3)° γ=90.00°
P-azoxyanisole form II
CrystEngComm (2008) 10, 3 279
a=14.9227(11)Å b=4.41484(7)Å c=10.3539(3)Å
α=90° β=105.550(3)° γ=90°
Cytenamide form II
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=5.8100(2)Å b=19.6315(5)Å c=21.7087(6)Å
α=85.918(2)° β=86.164(2)° γ=84.482(2)°
Cytenamide form I
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=33.9078(10)Å b=33.9078(10)Å c=5.6754(2)Å
α=90° β=90° γ=120°
C7H7NO,C7H5FO2
C7H7NO,C7H5FO2
CrystEngComm (2011) 13, 10 3349
a=8.0544(12)Å b=6.9420(10)Å c=22.058(4)Å
α=90° β=95.990(7)° γ=90°
C14H12FNO3
C14H12FNO3
CrystEngComm (2011) 13, 10 3349
a=10.046(2)Å b=10.573(2)Å c=11.461(2)Å
α=90° β=91.16(2)° γ=90°
3-fluorobenzoic acid 4-acetylpyridine
C14H12FNO3
CrystEngComm (2011) 13, 10 3349
a=10.105(4)Å b=10.734(4)Å c=11.806(4)Å
α=90° β=91.08(3)° γ=90°
3-fluorobenzoic acid 4-acetylpyridine
C14H12FNO3
CrystEngComm (2011) 13, 10 3349
a=7.9892(15)Å b=6.9703(14)Å c=21.947(4)Å
α=90° β=95.670(12)° γ=90°
3-fluorobenzoic acid 4-acetylpyridine
C7H7NO,C7H5FO2
CrystEngComm (2011) 13, 10 3349
a=7.9200(11)Å b=6.9633(9)Å c=21.918(4)Å
α=90° β=95.337(5)° γ=90°
3-Fluorobenzoic acid--4-acetylpyridine (1/1)
C7H5FO2,C7H7NO
CrystEngComm (2011) 13, 10 3349
a=10.0498(11)Å b=10.5779(8)Å c=11.5045(8)Å
α=90° β=92.026(4)° γ=90°
C7H7NO,C7H5FO2
C7H7NO,C7H5FO2
CrystEngComm (2011) 13, 10 3349
a=10.0714(15)Å b=10.6513(12)Å c=11.6320(13)Å
α=90° β=91.677(5)° γ=90°
5H-dibenz(b,f)azepine-5-carboxamide 2-(1-((4- chlorophenyl)carbonyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid (1/1)
C15H12N2O1,C19H16Cl1N1O4
CrystEngComm (2011) 13, 21 6327
a=10.2447(3)Å b=29.148(1)Å c=10.2114(3)Å
α=90° β=106.636(2)° γ=90°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.8746(14)Å b=6.4011(10)Å c=8.980(3)Å
α=74.05(2)° β=83.54(2)° γ=80.468(18)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.835(3)Å b=6.310(2)Å c=8.895(7)Å
α=74.62(4)° β=84.12(5)° γ=80.67(4)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.760(2)Å b=6.1455(12)Å c=8.737(4)Å
α=76.06(3)° β=84.56(3)° γ=81.25(2)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.728(2)Å b=6.0501(14)Å c=8.684(5)Å
α=76.54(3)° β=84.73(4)° γ=81.67(3)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.693(2)Å b=5.9013(14)Å c=8.599(5)Å
α=77.48(3)° β=84.97(4)° γ=82.35(3)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.676(3)Å b=5.8115(17)Å c=8.543(6)Å
α=77.95(4)° β=85.11(5)° γ=82.77(4)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.5100(5)Å b=5.9287(6)Å c=8.503(3)Å
α=76.528(16)° β=85.624(17)° γ=83.203(8)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.4832(4)Å b=5.8932(4)Å c=8.465(2)Å
α=76.234(13)° β=85.836(13)° γ=83.284(6)°
C7H6Cl1N3O4S2
C7H6Cl1N3O4S2
CrystEngComm (2010) 12, 9 2533
a=4.4609(4)Å b=5.8592(5)Å c=8.427(2)Å
α=75.991(15)° β=86.055(14)° γ=83.349(6)°
C28H52Cu4I4N4
C28H52Cu4I4N4
Dalton transactions (Cambridge, England : 2003) (2014) 43, 25 9448-9455
a=19.7281(6)Å b=19.7281(6)Å c=19.7281(6)Å
α=90.00° β=90.00° γ=90.00°
C24H52Cu4I4N4
C24H52Cu4I4N4
Dalton transactions (Cambridge, England : 2003) (2014) 43, 25 9448-9455
a=9.9963(7)Å b=9.9963(7)Å c=18.114(2)Å
α=90.00° β=90.00° γ=90.00°
?5a?
C28H52Cu4I4N4O4
Dalton transactions (Cambridge, England : 2003) (2014) 43, 25 9448-9455
a=19.9029(2)Å b=19.9029(2)Å c=19.9029(2)Å
α=90° β=90° γ=90°
C28H52Cu4I4N4O4
C28H52Cu4I4N4O4
Dalton transactions (Cambridge, England : 2003) (2014) 43, 25 9448-9455
a=37.444(4)Å b=12.2662(8)Å c=20.000(2)Å
α=90.00° β=113.38(1)° γ=90.00°
C24H26N2O6S
C24H26N2O6S
Organic letters (2013) 15, 6 1386-1389
a=7.52030(10)Å b=11.50070(10)Å c=13.57270(10)Å
α=90.00° β=100.4960(10)° γ=90.00°
Αβ-<i>D</i>-Lactose
C12H22O11
Acta Crystallographica Section C (2019) 75, 7
a=5.0044(3)Å b=38.6364(14)Å c=7.6007(4)Å
α=90° β=106.200(5)° γ=90°
Tetrachlorobenzene - alpha polymorph
C6H2Cl4
Acta Crystallographica Section B (2006) 62, 2 287-295
a=3.8016(5)Å b=10.6369(15)Å c=9.4866(13)Å
α=92.072(2)° β=98.966(2)° γ=96.520(2)°
1,2,4,5-tetrachlorobenzene - alpha polymorph
C6Cl4D2
Acta Crystallographica Section B (2006) 62, 2 287-295
a=3.79900(10)Å b=10.62580(10)Å c=9.47938(7)Å
α=91.9780(9)° β=99.058(2)° γ=96.234(2)°
1,2,4,5-tetrachlorobenzene - beta polymorph
C6Cl4D2
Acta Crystallographica Section B (2006) 62, 2 287-295
a=3.78988(4)Å b=10.50328(5)Å c=9.56244(3)Å
α=90° β=99.7184(6)° γ=90°
1,2,4,5-tetrachlorobenzene - beta polymorph
C6Cl4D2
Acta Crystallographica Section B (2006) 62, 2 287-295
a=3.85595(5)Å b=10.61473(6)Å c=9.59283(4)Å
α=90° β=99.6884(7)° γ=90°
1,2,4,5-tetrachlorobenzene - beta polymorph
C6Cl4D2
Acta Crystallographica Section B (2006) 62, 2 287-295
a=3.81117(4)Å b=10.53867(4)Å c=9.57198(3)Å
α=90° β=99.7088(5)° γ=90°
1,2,4,5-tetrachlorobenzene - alpha polymorph
C6Cl4D2
Acta Crystallographica Section B (2006) 62, 2 287-295
a=3.76062(4)Å b=10.58794(5)Å c=9.44562(3)Å
α=92.4066(4)° β=98.6978(6)° γ=97.5893(6)°
O-acetoamidobenzoic acid alpha polymorph
C9H10N2O2
Acta Crystallographica Section B (2006) 62, 5 926-930
a=4.8591(12)Å b=14.395(3)Å c=12.250(3)Å
α=90.00° β=92.151(16)° γ=90.00°
O-acetoamidobenzoic acid beta polymorph
C9H10N2O2
Acta Crystallographica Section B (2006) 62, 5 926-930
a=7.7880(10)Å b=8.972(2)Å c=12.547(2)Å
α=90.00° β=101.120(10)° γ=90.00°
Chlorothiazide
C7H6Cl1N3O4S2
Acta Crystallographica Section B (2008) 64, 1 101-107
a=4.8499(3)Å b=6.3694(4)Å c=8.9106(6)Å
α=74.4010(10)° β=83.8650(10)° γ=80.5240(10)°
Hydrochlorothiazide form II
C7H8Cl1N3O4S2
Acta Crystallographica Section B (2008) 64, 1 101-107
a=9.4855(3)Å b=8.3325(2)Å c=15.1201(4)Å
α=90° β=113.240(3)° γ=90°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8481(16)Å b=6.359(2)Å c=8.900(3)Å
α=74.49(3)° β=83.90(3)° γ=80.53(3)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8619(17)Å b=6.377(2)Å c=8.926(3)Å
α=74.40(3)° β=83.93(3)° γ=80.56(3)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8707(9)Å b=6.3951(12)Å c=8.9448(16)Å
α=74.368(16)° β=83.786(14)° γ=80.459(15)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8737(9)Å b=6.4046(13)Å c=8.9548(16)Å
α=74.324(17)° β=83.751(15)° γ=80.449(16)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8786(9)Å b=6.4126(13)Å c=8.9665(16)Å
α=74.266(16)° β=83.693(15)° γ=80.445(16)°
Famotidine
C8H15N7O2S3
Journal of Applied Crystallography (2002) 35, 4 443-454
a=17.6547(4)Å b=5.29320(10)Å c=18.2590(3)Å
α=90.0° β=123.5580(10)° γ=90.0°
N-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]- 3-[2-(2-naphthalen-1-ylethoxy)ethylsulfonyl]propylaminium benzoate
C26H31N2O5S2,C7H5O2
Acta Crystallographica Section E (2004) 60, 10 o1751-o1753
a=7.63122(17)Å b=13.6673(3)Å c=15.8058(5)Å
α=84.385(2)° β=87.4653(19)° γ=75.7135(13)°
Dibenz[a,c]anthracene
C22H14
Acta Crystallographica Section E (2005) 61, 5 o1483-o1485
a=18.2966(5)Å b=5.06225(10)Å c=15.7245(4)Å
α=90° β=104.5574(15)° γ=90°
3-Azabicyclo[3.3.1]nonane-2,4-dione
C8H11N1O2
Acta Crystallographica Section E (2006) 62, 7 o3046-o3048
a=7.67102(18)Å b=10.5483(2)Å c=18.8867(4)Å
α=90° β=95.5800(12)° γ=90°
Hydrochlorothiazide form II
C7H8ClN3O4S2
Acta Crystallographica Section E (2005) 61, 9 o2798-o2800
a=9.4884(5)Å b=8.3334(4)Å c=15.1309(7)Å
α=90° β=113.2087(19)° γ=90°
Chlorothiazide dimethylformamide solvate
C7H6ClN3O4S2,C3H7NO
Acta Crystallographica Section E (2006) 62, 6 o2216-o2218
a=7.9822(4)Å b=8.8830(5)Å c=11.1075(6)Å
α=86.689(3)° β=75.078(3)° γ=73.196(3)°
Hydrochlorothiazide--methyl acetate (1/1)
C7H8ClN3O4S2,C3H6O2
Acta Crystallographica Section E (2005) 61, 9 o2974-o2977
a=9.39703(16)Å b=7.28424(16)Å c=21.9483(3)Å
α=90° β=95.8020(11)° γ=90°
(R)-1-phenylethylammonium (R)-2-phenylbutyrate
C8H12N,C10H11O2
Acta Crystallographica Section E (2007) 63, 1 o247-o249
a=6.06200(10)Å b=16.7794(3)Å c=16.8881(4)Å
α=90° β=90° γ=90°
2(C10H9N1O2),C6H6O2
2(C10H9N1O2),C6H6O2
Acta Crystallographica Section E (2007) 63, 6 o2891-o2891
a=7.8841(19)Å b=8.480(2)Å c=9.887(3)Å
α=95.72(2)° β=109.85(3)° γ=113.50(2)°
7-Fluoroisatin--1,4-dioxane (1/1)
C12H12FNO4
Acta Crystallographica Section E (2007) 63, 8 o3574-o3574
a=11.5274(3)Å b=8.6508(2)Å c=12.1738(4)Å
α=90° β=106.701(3)° γ=90°
Trichlormethiazide
C8H8Cl3N3O4S2
Acta Crystallographica Section E (2007) 63, 9 o3685-o3685
a=8.7881(2)Å b=9.7924(2)Å c=15.8527(3)Å
α=90.00° β=90.00° γ=90.00°
Carbamazepine trifluoroacetic acid solvate
C15H12N2O,C2HF3O2
Acta Crystallographica Section E (2007) 63, 11 o4269-o4269
a=15.0142(4)Å b=5.28710(10)Å c=20.2489(6)Å
α=90.00° β=101.735(3)° γ=90.00°
Urea DMF solvate (3/1)
C3H7NO,3(CH4N2O)
Acta Crystallographica Section E (2007) 63, 12 o4861-o4861
a=7.5246(13)Å b=9.866(4)Å c=10.821(4)Å
α=65.61(4)° β=79.43(2)° γ=70.76(2)°
Cytenamide acetic acid solvate
C16H13NO,C2H4O2
Acta Crystallographica Section E (2008) 64, 6 o1175-o1176
a=5.8726(17)Å b=14.418(3)Å c=18.182(4)Å
α=90° β=95.13(2)° γ=90°
10,11-Dihydrocarbamazepine--dimethyl sulfoxide (1/1)
C15H14N2O1,C2H6OS
Acta Crystallographica Section E (2007) 63, 9 o3918-o3919
a=10.2696(3)Å b=6.8543(2)Å c=23.3599(6)Å
α=90.00° β=98.932(2)° γ=90.00°
Dihydrocarbamazepine Form III
C15H14N2O1
Acta Crystallographica Section E (2007) 63, 2 o675-o677
a=5.4233(12)Å b=9.200(5)Å c=24.189(6)Å
α=87.59(3)° β=84.23(2)° γ=88.93(3)°
3-azabicyclo[3.3.1]nonane-2,4-dione 1-methylnaphthalene hemisolvate
C8H11NO2,0.5C11H10
Acta Crystallographica Section E (2006) 62, 9 o3752-o3754
a=15.02360(18)Å b=7.32295(12)Å c=22.5164(3)Å
α=90° β=106.0201(6)° γ=90°
Hydroflumethiazide dimethylsulfoxide disolvate
C8H8F3N3O4S2,2C2H6OS
Acta Crystallographica Section E (2007) 63, 10 o3956-o3956
a=5.55700(10)Å b=20.8433(4)Å c=17.4142(3)Å
α=90.00° β=93.540(2)° γ=90.00°
Urea--dimethylacetamide
C4H9NO,CH4N2O
Acta Crystallographica Section E (2008) 64, 2 o355-o355
a=7.2770(3)Å b=17.5394(9)Å c=7.3789(4)Å
α=90° β=119.450(3)° γ=90°
Triphenylphosphine oxide--hydroquinone (1/1)
C18H15OP,C6H6O2
Acta Crystallographica Section E (2008) 64, 2 o367-o367
a=8.927(4)Å b=9.3576(10)Å c=14.459(4)Å
α=71.157(7)° β=73.826(6)° γ=62.83(2)°